Table 2.
Disease presentation and responses to each VST infusion
| Total subjects | Donor-derived VST | Third-party VST | |
|---|---|---|---|
| Indication for VST, n | N = 38 | N = 14 | N = 24 |
| Viremia | 20 | 6 | 14 |
| Cystitis | 4 | 2 | 2 |
| Viremia + cystitis | 14 | 6 | 8 |
| BK infection presentation before VST infusion | |||
| Viremia | |||
| Days post-HSCT BKPyV was detected, median (range) | 29 (5-187) | 21 (5-74) | 35 (10-187) |
| BKPyV before first VST infusion, median (range), copies/mL | 8 243 (135-5 513 000) | 2 100 (135-1 440 951) | 12 543 (1 000-5 513 000) |
| Hemorrhagic cystitis | |||
| Days post-HSCT cystitis diagnosis, median (range) | 22 (2-121) | 15 (2-61) | 26 (10-121) |
| Cystitis grade before VST infusion, n | |||
| 2 | 10 | 4 | 6 |
| 3 | 6 | 3 | 3 |
| 4 | 2 | 1 | 1 |
| Antiviral therapy at the time of first VST infusion, n | |||
| Cidofovir | 14 | 4 | 10 |
| Acyclovir | 23 | 9 | 14 |
| Ganciclovir | 3 | 2 | 1 |
| Foscarnet | 2 | 1 | 1 |
| Response VTS | |||
| BKPyV response | |||
| CR, % | 69 | 58 | 77 |
| PR, % | 17 | 17 | 18 |
| CR+PR, % | 86 | 75 | 95 |
| NR, % | 14 | 2% | 5 |
| BKPyV after last VST infusion, median (range), copies/mL | 2 357 (0-1 590 000) | 1 800 (0-2 800) | 2 681 (0-1 590 000) |
| Cystitis response, % | |||
| CR | 75 | 50 | 100 |
| PR | 25 | 50 | 0 |
| CR+PR | 100 | 100 | 100 |
| NR | 0 | 0 | 0 |
| BKPyV + cystitis response | |||
| CR, % | 58 | 60 | 57 |
| PR, % | 29 | 27 | 30 |
| CR+PR, % | 87 | 87 | 87 |
| NR, % | 13 | 13 | 13 |
| Number of VST infusions, median (range) | 1 (1-3) | 1 (1-10) | |
| Infusion reaction, n | 0 | 0 | 0 |
| aGVHD within 30 d of VST infusion, n | 1 | 0 | 1 |
aGVHD, acute graft-versus-host disease; NR, no response.